Based on the known fact that the parathyroid hormone (PTH) might be extended at its C-terminus with biotechnological protein cargoes, a vector directing the secretion of PTH 1-84 C-terminally fused with the antigenic epitope myc (PTH-myc) was exploited. The functional properties and potential of this analog for imaging PTH 1 R-expressing cells were examined. The PTH-myc construct was recombinantly produced as a conditioned medium (CM) of transfected HEK 293a cells (typical concentrations of 187 nM estimated with ELISAs for PTH). PTH-myc CM induced cyclic AMP formation (10 min), with a minor loss of potency relative to authentic PTH 1-84 , and c-Fos expression (1-3 h). Treatment of recipient HEK 293a cells transiently expressing PTH 1 R with PTH-myc CM (supplemented with a fluorescent monoclonal anti-myc tag antibody, either 4A6 or 9E10 -arrestin 1 (microscopy, cytofluorometry). Authentic PTH was inactive in this respect, ruling out a nonspecific form of endocytosis like pinocytosis. Using a horseradish peroxidase-conjugated secondary antibody, the endocytosis of the PTH-myc-based antibody complex by endogenous PTH 1 R was evidenced in MG-63 osteoblastoid cells. The secreted construct PTH-myc represent a bona fide agonist that support the feasibility of transporting cargoes of considerable molecular weight inside cells using arrestin and Rab5-mediated PTH 1 R endocytosis. PTH-myc is also transported into cells that express PTH 1 R at a physiological level. Such tagged peptide hormones may be part of a cancer chemotherapy scheme exploiting a modular cytotoxic secondary antibody and the receptor repertoire expressed in a given tumor. Recent crystal structures of agonist-bound PTH 1 R extracellular domain revealed that the Cterminal hormone residue does not form direct contacts with the receptor [16]. This made possible two recent biotechnological forms of PTH 1-34 -based agonists elongated at their C-
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Introduction
The parathyroid hormone (PTH) is an 84 aminoacid peptide that is a major regulator of bone metabolism and calcium ion handling by tissues via its G protein coupled PTH 1 receptor (PTH 1 R) expressed in kidneys and the skeleton [14] . Synthetic PTH and its PTH fragment (teriparatide) are currently therapeutically used for an anti-osteoporosis effect [21] and the osteoblast is believed to be their site of action. Furthermore, in a recently reported preclinical model of joint trauma relevant for the physiopathology of osteoarthritis, systemically administered PTH was further proposed to be chondroprotective and chondroregenerative via PTH 1 Rs upregulated in chondrocytes [18] . Indeed, PTH is anabolic for cartilage and the serum concentration of the hormone is correlated to cartilage metabolic activity (leucine and sulfate incorporation) in juvenile mice [24] . Further, PTH 1 R is expressed in various tumor cells [13, 17] . PTH 1 R is subjected to agonist--arrestin-dependent internalization [9] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5 potential in cells expressing recombinant or natural PTH 1 Rs. PTH-myc is part of a growing set of myc-tagged agonist peptide hormones that transport antibodies into cells via arrestin-mediated GPCR cycling (bradykinin B 2 receptor [8] ; CC-chemokine receptor 7 [4] ). 1 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6
Materials and methods

Cell culture, transfection and analysis
A subclone of HEK 293 cells, called HEK 293a, originally obtained from Sigma-Aldrich was used in most supplemented with 10 % FBS, 1 % L-glutamine and 1 % penicillin-streptomycin stock solutions (100 ). The cells were used as recipients of a vector purchased from OriGene Technologies (Rockville, MD): myc-DDK-tagged pro-PTH, that directs the secretion of the mature human PTH 1-84 sequence extended at its C-terminus with 2 epitopes in tandem, myc and DDK (catalog number RC519848; translated amino acid sequence in Fig. 1 ). The latter construction will be conventionally designated as PTH-myc. Seventy % confluent producer cells were transfected with a given vector using the ExGen reagent (Fermentas) used as directed.
Other recipient HEK 293a cells were grown and transiently transfected as described above with a vector coding for PTH 1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7   microscope coupled to a CoolSnap HQ digital camera (filters for AlexaFluor-488: excitation The TSA technology applied to immunohistochemistry is reviewed elsewhere [23] . 8
Immunoblots
The agonist action of PTH-related agonists was investigated using the expression of the transcription factor c-Fos, a distal signaling response to the stimulation of various receptor-ligand systems [10] . Total HEK 293a cell extracts were immunoblotted to detect c-Fos expression using the K-25 rabbit polyclonal antibodies (Santa Cruz Biotechnology; dilution 1:100).
ELISA of cyclic AMP and PTH
A commercial cyclic AMP ELISA kit (Cell Biolabs, San Diego, CA) was applied as directed without the optional acylation reaction to quantify the intracellular second messenger of PTH 1 R- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9
Results
Characterization of PTH-myc as carrier of an antibody cargo: visualization tool
The CM of HEK 293a cells transiently transfected with the vector coding for the tagged protein PTH-myc contained the equivalent of 187 ± 15 nM of PTH (ELISA for full sequence PTH, n = 3). The control CM of untransfected cells did not contain measurable immunoreactive PTH (n = 2). In acute tests (10-min stimulation), PTH-myc was about 4-fold less potent than PTH 1-84 to raise cyclic AMP in HEK 293a cells that expressed recombinant PTH 1 R (ELISA determinations, Experiments were designed to evidence the PTH 1 R-mediated cellular uptake of immune complexes formed in the culture medium and composed of PTH-myc bound to a fluorescent antimyc antibody (microscopy, Figure 4 , or cytofluorometry, Figure 5 ). Controls included cells that did not express PTH 1 R, cells stimulated with synthetic PTH 1-84 (10-100 nM) or with the CM of untransfected HEK 293a cells. A very robust and specific endosomal labeling of recipient cells that expressed the receptor was observed ( Figure 4 ). These observations support that the PTH- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 myc-4A6 ( Fig. 4A ) or PTH-myc-9E10 immune complexes ( Fig. 4B ) formed in the culture medium were recognized by the PTH 1 R as agonists and were transported into endosomes.
Cytofluorometry confirmed these results (based on the fluorescent 4A6 antibody, Figure 5 ). Of note, synthetic PTH 1-84 devoid of the myc epitope was not competent to induce the endocytosis Colocalization of the PTH-myc-fluorescent anti-myc antibody complex was also tested in cells expressing the receptors and one of two Rab5-mCherry constructions: the GTP-locked activated form that causes the formation of giant endosomes [19] or the wild type one (Figure 7) :
colocalization was extensive in cells treated for 30 min with the CM of PTH-myc. Rab5 is a marker of early endosomes, whereas Rab7 rather labels late endosomes. While the PTH-myc/4A6 did not colocalize with Rab7-mCherry after 30 min of incubation, minor colocalization was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   11 observed after 3 or 6 h (Figure 8 ), indicating a slow progress of the antibody cargo in the endosomal/lysosomal tract.
Application of PTH-myc to imaging of endogenously expressed PTH 1 R
In HEK 293a cells that express PTH 1 R, but not in control cells, a very bright intracellular signal was detected following endocytosis of the PTH-myc-4A6 antibody complex using the TSA system that enzymatically generates AlexaFluor-488 labeling ( Figure 9A ). This amplified detection system has been applied to detect the naturally expressed PTH 1 R in relevant cells.
The human osteoblastoma MG63 cell line is known to express PTH 1 R and to functionally respond in several ways to PTH 1-84 , PTH 1-34 and other ligands [5, 11, 12, 25] . This cell line exhibits a slight but consistent granular uptake of the AlexaFluor-488-conjugated anti-myc antibody if cotreated with PTH-myc CM, but not when exposed to the control CM of HEK 293a cells (microscopy, Figure 9B ). The enzymatically amplified TSA detection system, based on a HRPconjugated secondary antibody, revealed the endocytosis of the 4A6 antibody-PTH-myc complex in a more intense manner with some non-specific nuclear staining ( Figure 9B) . These experiments establish that the same hierarchy of sensitivities for PTH 1 R visualization techniques exists in MG-63 cells as in HEK 293a cells that express recombinant receptors, but lower intensities in the system that expresses low physiological levels of PTH 1 R. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12
Discussion
Because the secretin receptor family is tolerant to variations in the C-terminal structure of peptide ligands [7] , we hypothesized that PTH-myc, efficiently secreted and combined in the extracellular milieu with an anti-myc antibody, would support the endocytosis of a very large agonist cargo (in excess of 150 kDa) mediated by recombinant or naturally expressed PTH 1 R (Figures 4-10 ). PTH-myc is a close analog of the full hormone sequence and both increased cellular cyclic AMP ( Fig. 2) and exert a prolonged effect on the c-Fos expression assay ( Figure   3 ). The recombinant peptide PTH-myc has been compared to synthetic PTH 1-84 in the assay of acute cyclic AMP generation ( Fig. 3 ), but not in the slow c-Fos induction assay ( Fig. 4) , where arbitrary agonist concentrations were used; the former assay evidence only a minor loss of potency in the myc-tagged agonist. Findings suggest that binding of the tagged agonist to the antibody does not impair the recognition of the receptor by PTH and that this design enables protein cargoes even larger than green fluorescent protein [3] to be transported by the activated PTH 1 R. The anti-myc 4A6 monoclonal antibody used in the present work has previously been shown to be internalized by the activated bradykinin B 2 receptors, whether the myc epitope was located in the receptor construction or at the N-terminus of a synthetic agonist [2, 8] , and also by the chemokine receptor CCR7 via a myc-tagged agonist (CCL19-myc) [4] . The alternate 9E10
anti-myc monoclonal antibody was also internalized as a cargo tightly bound to the agonist PTHmyc, despite its more unpredictable behavior vs. sequences that flank the myc epitope in protein constructions [1] . We have not exploited the built-in DDK epitope present in the commercial PTH-myc construction (Fig. 1) , because a typical commercial anti-DDK tag is both less sensitive and specific than the anti-myc monoclonals in our hands. Importantly, results highlight that detection of the co-endocytosed 4A6 monoclonal antibody using an enzymatically amplified 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 reaction is a powerful visualization aid for the PTH 1 R that proved cargo endocytosis by endogenously expressed receptors in the osteoblastoid cells MG-63.
The anti-osteoporosis peptide PTH 1-34 is inactivated by receptor-expressing cells and has a short duration of action inosteoblast that is believed to be obligatory for the desired anabolic effect [22] . The PTH-myc construction is based on the PTH 1-84 sequence known to undergo massive receptor-mediated endocytosis and that determines slow intracellular cycling relative to the alternate agonist PTHrelated peptide (PTHrP) [22] . Further highlighting the complexity of this system, recent evidence supports that non-canonical signaling emerging from endocytosed PTH 1 -arrestins may also impact the relative therapeutic efficacy of these analogs [9, 22] . These observations may reflect different cycling and signaling kinetics relative to the parent peptides. Although beyond the scope of the present study (focused on imaging applications), such future analyses will be important to better understand how heavy C-terminal modifications impact the pharmacological properties of emerging class B GPCR agonist therapeutics. For instance, albiglutide is a new antidiabetic glucagon-like peptide 1 receptor agonist fused to albumin; this fusion protein exhibits considerable alteration of pharmacokinetics relative to the parent peptide [20] .
Altering the cargo protein at the C-terminus of the PTH 1 R activating sequence could lead to more ambitious applications that are not currently supported by the present study. (1) In relationship to the recently proposed use of a systemically administered PTH 1 R agonist in osteoarthritis [18] , the present study suggests the possibility to produce alternate high molecular weight agonists adapted to intra-articular injection with decreased systemic diffusion, prolonged signaling and decreased (2) Further, a functional cytotoxic protein cargo conjugated to PTH 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 could theoretically be useful to treat malignant chondrosarcomas, where PTH 1 R expression is consistently upregulated in a manner correlated with histological grade [17] . PTH 1 R is also expressed in an apparently ectopic manner in a number of human carcinomas (e.g., prostate, pancreas) [13] . In such application, a novel generation of anti-myc monoclonal antibodies armed with cytotoxic drugs via acid-labile bonds that are released in endosomes [15] could be targeted to tumor cells that express PTH 1 R (as modeled in MG-63 cells). The strategy is modular, being adaptable to other tagged agonists, for instance CCL19-myc, an agonist of CCR7 often expressed in metastatic tumors [4] . The agonist effect of the peptide hormone vector, documented for PTHmyc, would not necessarily be detrimental because the transient stimulation of tumor cell mitosis or metabolism could selectively increase their sensitivity to anti-mitotic drugs conjugated to the secondary antibody.
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